本次控股孙公司获证的医用电子内窥镜图像处理器及电子支气管镜，是莱美医疗器械研发的内窥镜产 品，该产品能直接观察患者图像，有利于临床使用对患者病症的判断及治疗。此次控股孙公司产品获证 将进一步丰富公司医疗器械产品种类，满足市场多样化的需求，提升公司综合竞争力，对未来经营将产 生积极影响。 财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：安东 格隆汇12月10日丨中恒集团(600252.SH)公布，近日，公司控股子公司重庆莱美药业股份有限公司之子 公司海南莱美医疗器械有限公司收到海南省药品监督管理局颁发的两项《医疗器械注册证》。 产品名称：医用电子内窥镜图像处理器，注册证编号：琼械注准20252060115；产品名称：电子支气管 镜，注册证编号：琼械注准20252060116。 ...

Group 1 - The core point of the article is that Zhongheng Group announced the receipt of two medical device registration certificates for its subsidiary, Hainan Laimei Medical Equipment Co., Ltd., from the Hainan Provincial Drug Administration, including a "medical electronic endoscope image processor" [1] - For the fiscal year 2024, Zhongheng Group's revenue composition is as follows: 76.26% from pharmaceutical manufacturing, 13.84% from other businesses, and 9.9% from food [1] - As of the report date, Zhongheng Group has a market capitalization of 9.1 billion yuan [1]

Core Viewpoint - Zhongheng Group announced that its subsidiary, Chongqing Laimei Pharmaceutical Co., Ltd., received two medical device registration certificates from the Hainan Provincial Drug Administration for its medical electronic endoscope image processor and electronic bronchoscope, which are beneficial for clinical diagnosis and treatment of patients [1] Group 1 - The medical devices certified include an electronic endoscope image processor and an electronic bronchoscope [1] - The products developed by Laimei Medical Equipment allow direct observation of patient images, aiding in clinical judgment and treatment of conditions [1]

每经AI快讯，12月10日，中恒集团(600252.SH)公告称，公司控股子公司重庆莱美药业之子公司海南莱 美医疗器械有限公司近日收到海南省药品监督管理局颁发的两项《医疗器械注册证》，分别是医用电子 内窥镜图像处理器和电子支气管镜，有效期均为2025年11月17日至2030年11月16日。该产品能直接观察 患者图像，有利于临床使用对患者病症的判断及治疗。此次产品获证将进一步丰富公司医疗器械产品种 类，满足市场多样化的需求，提升公司综合竞争力，对未来经营将产生积极影响。 ...

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

智通财经APP讯，莱美药业(300006.SZ)公告，公司控股子公司海南莱美医疗器械有限公司(简称"莱美医 疗器械")收到海南省药品监督管理局颁发的两项《医疗器械注册证》，产品名称为：医用电子内窥镜图 像处理器、电子支气管镜。 ...

格隆汇12月10日丨莱美药业(300006.SZ)公布，控股子公司海南莱美医疗器械有限公司（简称"莱美医疗 器械"）收到海南省药品监督管理局颁发的两项《医疗器械注册证》，本次公司控股子公司获证的医用 电子内窥镜图像处理器及电子支气管镜，是莱美医疗器械研发的内窥镜产品，该产品能直接观察患者图 像，有利于临床使用对患者病症的判断及治疗。此次公司控股子公司产品获证将进一步丰富公司医疗器 械产品种类，满足市场多样化的需求，更将提升公司综合竞争力，对未来经营将产生积极影响。 ...

每经头条（nbdtoutiao）——最新1520元，飞天茅台批价两年跌了43%，经销商躺赢神话破灭，当潮水 退去谁在裸泳？ （记者 曾健辉） 每经AI快讯，莱美药业12月10日晚间发布公告称，近日，重庆莱美药业股份有限公司控股子公司海南 莱美医疗器械有限公司收到海南省药品监督管理局颁发的两项《医疗器械注册证》。包括"医用电子内 窥镜图像处理器"等产品。 ...

格隆汇12月10日丨莱美药业(300006.SZ)公布，控股子公司海南莱美医疗器械有限公司（简称"莱美医疗 器械"）收到海南省药品监督管理局颁发的两项《医疗器械注册证》，本次公司控股子公司获证的医用 电子内窥镜图像处理器及电子支气管镜，是莱美医疗器械研发的内窥镜产品，该产品能直接观察患者图 像，有利于临床使用对患者病症的判断及治疗。此次公司控股子公司产品获证将进一步丰富公司医疗器 械产品种类，满足市场多样化的需求，更将提升公司综合竞争力，对未来经营将产生积极影响。 ...